Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa Nasdaq:NVAX

  • Phase 2b clinical trial in collaboration with Professor Shabir Madhi and Wits University
  • Bill & Melinda Gates Foundation providing $15 million grant toward trial
  • Mature trial infrastructure along with significant levels of seasonal transmission may allow for rapid efficacy evaluation

GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373,…

Source link

About Author: ACM
This information is 3rd party content that is added to ACM strictly for non-commercial informational purposes. Information is the Key to Set the Black Mind Free